London, May 7th – Ailurus, a leading company in programming biology, is excited to announce the launch of its startup plan for PandaPure, a revolutionary technology that streamlines protein expression and purification. This initiative is designed to support early-stage startups in the biotechnology sector, providing them with advanced tools to accelerate their research and development efforts.

Through this program, eligible startups who purchase PandaPure toolkits can request an additional license for commercial purposes without extra fee, allowing them to manufacture bioproducts and provide fee-for services to third parties. This offering enables startups to explore commercial applications with the financial burden of licensing fees or royalty shares, as long as the company continues to meet the criteria.

To qualify for the startup plan, companies must meet the following criteria:
- Have fewer than 50 employees
- Aggregate funding of $25 million or less
- Annual recurring revenue (ARR) of $1 million or less

"Recombinant proteins represent a significant portion of bioproducts in the market, from biologics for therapeutics to biocatalysts for green chemistry," said Dr. Haotian Guo, the CEO of Ailurus. "With our startup plan, we aim to democratize access to this cutting-edge technology, empowering early-stage startups to drive innovation in the bioeconomy."

Key benefits of PandaPure include:
1. Easy expression of a wide range of difficult proteins
2. Significant reduction in the cost and complexity of protein purification

To learn more about PandaPure technology and the free startup plan, please visit PandaPure website.